CANDEL THERAPEUTICS INC (CADL) Stock Earnings & Estimates
USA - NASDAQ:CADL - US1374041093 - Common Stock
4.92 USD
-0.1 (-1.99%)
4.95 USD
+0.03 (+0.61%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 125K | 125K | 125K | -100.00% | 70.107M | 191.46M 173.10% | 407.86M 113.03% | 680.37M 66.81% | 739.12M 8.64% | 1.214B 64.25% | ||||
| EBITDA YoY % growth | -13.719M -52.54% | -25.494M -85.83% | -33.944M -33.15% | -34.996M -9.09% | -35.067M 12.56% | -43.359M -33.90% | -65.393M -50.82% | -37.846M 42.13% | 240.18M 734.63% | 670.49M 179.16% | 1.203B 79.42% | 55.386M -95.40% | N/A | |
| EBIT YoY % growth | -13.81M -52.82% | -25.726M -86.29% | -34.722M -34.97% | -38.046M -9.41% | -35.512M 12.16% | -44.363M -32.94% | -64.266M -44.86% | -20.843M 67.57% | 143.85M 790.16% | 365.79M 154.29% | 624.03M 70.60% | 495.17M -20.65% | 666.89M 34.68% | |
| Operating Margin | -11,048.00% | -20,580.80% | -27,777.60% | N/A | N/A | N/A | N/A | -29.73% | 75.13% | 89.69% | 91.72% | 66.99% | 54.93% | |
| EPS YoY % growth | N/A | N/A | -1.12 46.21% | -1.11 -21.43% | -1.40 -2.69% | -0.37 73.64% | -0.92 -148.94% | -0.42 54.67% | N/A | N/A | N/A | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.19 | -0.24 40.73% | -0.17 -233.38% | -0.22 -149.33% |
| Revenue Q2Q % growth | ||||
| EBITDA Q2Q % growth | -11.895M -48.47% | -12.324M -72.33% | -9.792M -24.19% | -12.24M -14.50% |
| EBIT Q2Q % growth | -12.053M -37.64% | -12.703M -56.04% | -9.894M -21.70% | -12.444M -11.34% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.09 | -0.17 | 0.08 | 48.10% |
| Q1 2025 Q2Q % growth | 0.13 | -0.31 | 0.44 | 142.48% |
| Q4 2024 Q2Q % growth | -0.40 -5.26% | -0.23 | -0.17 | -72.38% |
| Q4 2023 Q2Q % growth | -0.38 -111.11% | -0.16 | -0.22 | -132.84% |
| Q3 2023 Q2Q % growth | -0.31 -3.33% | -0.19 | -0.12 | -59.96% |
| Q2 2023 Q2Q % growth | -0.34 -6.25% | -0.30 | -0.04 | -11.67% |
| Q1 2023 Q2Q % growth | -0.33 -3.13% | -0.36 | 0.03 | 7.56% |
| Q4 2022 Q2Q % growth | -0.18 -158.06% | -0.32 | 0.14 | 43.44% |
| Q3 2022 Q2Q % growth | -0.30 -15.38% | -0.36 | 0.06 | 16.68% |
| Q2 2022 Q2Q % growth | -0.32 -3.23% | -0.42 | 0.10 | 23.01% |
| Q1 2022 Q2Q % growth | -0.32 | -0.31 | -0.01 | -1.86% |
| Q4 2021 Q2Q % growth | 0.31 | -0.33 | 0.64 | 194.98% |
| Q3 2021 Q2Q % growth | -0.26 | -0.30 | 0.04 | 12.10% |
| Q2 2021 Q2Q % growth | -0.31 | -0.12 | -0.19 | -153.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2023 Q2Q % growth | -100.00% | % | ||
| Q3 2023 Q2Q % growth | -100.00% | % | ||
| Q2 2023 Q2Q % growth | -100.00% | % | ||
| Q1 2023 Q2Q % growth | -100.00% | % | ||
| Q4 2022 Q2Q % growth | 31K | 23.123K | 7.877K | 34.06% |
| Q3 2022 Q2Q % growth | 31K | 30.6K | 400 | 1.31% |
| Q2 2022 Q2Q % growth | 31K | 31K | % | |
| Q1 2022 Q2Q % growth | 31K | 15.3K | 15.7K | 102.61% |
| Q4 2021 Q2Q % growth | 31K | 15.3K | 15.7K | 102.61% |
| Q3 2021 Q2Q % growth | 31K | 40.8K | -9.8K | -24.02% |
| Q2 2021 Q2Q % growth | 31K | 20.4K | 10.6K | 51.96% |
| Q1 2021 Q2Q % growth | 31K | % |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -2.29% | 22.08% | -118.01% | 5.93% |
| Revenue | N/A | N/A | N/A | N/A |